Background: Few studies have described the demographics and outcomes in patients with multiple cancers. Methods: We reviewed the health records of patients with at least 3 invasive solid-tumor malignancies (lung, colorectal, pancreatic, prostate, breast, or ovarian) 
Introduction
Adult patients with cancer are living longer. 1 Zeng et al , respectively. These findings suggest that patients with cancer are living longer and that cancer can, at times, be viewed as a long-term disease. 2 Few studies have focused in general terms on patients who live for many years following a first diagnosis of cancer and then continue to be diagnosed with multiple cancers over time. 3, 4 Previous studies have described multiple cancers in adult patients with predisposing syndromes, showing, for example, that individuals with Lynch syndrome or BRCA1/BRCA2 mutations have a more favorable prognosis after cancer diagnoses.
5, 6 Others have described patients with therapy-related malignancies who have worse prognoses compared with their counterparts who develop de novo cancers. 7, 8 However, to our knowledge, these studies and others have not explored the presence of multiple cancers in the absence of predisposing syndromes or therapy-related secondary cancers.
Purpose
This study explored demographics and outcomes in patients who developed multiple cancers. Some patients contend with multiple malignancies throughout their lives, thus displaying a poorly characterized predisposition to cancer and a need for ongoing cancer surveillance. Reporting on the characteristics and outcomes of patients with multiple cancers might help oncologists better counsel patients about prognoses and realistic treatment goals in the setting of multiple malignancies.
Methods

Overview
This single-institution study focused on patients with cancer seen at the Mayo Clinic (Rochester, MN) from 1995 to 2014, encompassing a 20-year interval that saw national improvements in cancer outcomes. 2 The Mayo Clinic Tumor Registry, which relied in part on International Classification of Diseases codes, pathology reports, and other clinical sources to input data, was searched for patients who met study criteria.
Eligible patients had to be diagnosed between 1995 and 2014 with at least 3 invasive malignancies of at least 1 of the following types: lung, colorectal, pan-creatic, prostate, breast, or ovarian. These malignancies were chosen because they are among the most common and lethal in the United States and have 5-year relative survival rates of 16%, 59%, 7%, 95%, 85%, and 41%. 9 Inclusion criteria were determined a priori. No major changes occurred in the Mayo Clinic Tumor Registry or in institutional infrastructure within the interval above; hence, data retrieval uniformly occurred over time. The Institutional Review Board at the Mayo Clinic approved this study.
Medical Record Review
Each patient's health records were reviewed and abstracted for date of birth, sex, date of each cancer diagnosis, stage of each cancer, smoking history, family history of cancer (cancer in ≥ 2 first-degree relatives), documentation of genetic predisposition to cancer, cancer treatment, vital status, and date of death or last follow-up visit. Because definitions of predisposing syndromes to cancer have evolved over time to include clinical criteria and, in some instances, molecular criteria, the methodology congruent with a real-time contemporary standard was used in this study. If a date was not clearly documented, then a mid-month or midyear date was used. If the health record lacked clear documentation of an item, then an unknown category was used.
Data Analyses
Results are reported with means and percentages; all analyses are considered exploratory. Because patients were heavily selected based on 6 targeted cancer types, this study was not designed to report on the prevalence rates of patients with multiple cancers. Kaplan-Meier curves were constructed to assess survival, and data were censored as appropriate. Cox proportional hazard models were used to explore whether certain clinical variables were associated with survival. Variables were chosen based on their clinical relevance to cancer outcomes and based on a desire for parsimony to ensure stability of statistical models; in this context, age at cancer diagnosis, sex, smoking history, concurrent cancer diagnosis, stage IV disease (any malignancy), and cancer type at first diagnosis were chosen. HRs and 95% CIs were reported. A 2-tailed P value of less than .05 was considered statistically significant. All analyses were performed with JMP Statistical Software (SAS Institute, Carey, NC).
Results
Baseline Demographics
Nine patients were excluded because of lack of clarity as to whether 1 or more of their cancers represented a new malignancy, a metastatic site, or recurrence of a previous cancer. The remaining 163 patients are the focus of this report.
The median age of the study participants was 61 years (range, 24-87). Sixteen (10%) had cancer in at least 2 first-degree relatives, and 7 (4%) had a known syndrome that predisposed them to cancer. Other patient demographics appear in Table 1 .
Cancer Characteristics
Cancer of the breast, colorectum, and lung were the 3 most common cancer types in the study group (Table 2) . Seventy patients (43%) had more than 3 cancers. In 10 patients, the first cancer diagnosis did not fall within the 1995 to 2014 time interval, but these patients were eligible for the study because they developed 3 invasive cancers during this interval. The median interval from the first ever to the second cancer diagnosis was 2.6 years (range, 0-45), and the median interval from the first ever to the third cancer diagnosis was 6.2 years (range, 0-58; Fig 1) . Most patients had relatively early-stage malignancies, and the majority also underwent surgical treatment for all 3 cancers. Fewer than one-half of these specific cancers were treated with chemotherapy or radiotherapy. Cancer Outcomes A total of 92 patients (56%) had died. The median follow-up of patients still living was 11.4 years (range, 0.3-58.0). In 62 (67%) of the deceased patients, the cause of death was cancer; in 6 (7%), a nonmalignant cause was determined; and, in 24 (26%), the cause was unknown. The overall median survival for the entire group was 14 years from the time of first cancer diagnosis (95% CI: 12-16; Fig 2) . In univariate analyses, older age, male sex, a smoking history, a concurrent cancer diagnosis, and stage IV disease among any of the 3 malignancies yielded a statistically significant association with worse survival (Table 3) . Breast cancer as the first diagnosis of cancer was associated with improved survival. However, in multivariate analyses, older age, smoking history, and any diagnosis of stage IV disease yielded a statistically significant association with worse survival (see Table 3 ).
Among the 43 patients who had breast cancer as their first cancer, all were women. A total of 29 (69%) had a smoking history (median of 35 pack-years), 5 (12%) had a family history of cancer, and 2 had a documented genetic predisposition to cancer. The median age at first cancer diagnosis was 64 years (range, 33-80). Thirty-one patients (74%) were diagnosed with stage I disease. The remaining stage distribution included 5 with stage II, 5 with stage III, 1 with stage IV, and 1 whose stage was unknown. A total of 41 patients (95%) were treated with surgery for the first cancer, 26 (60%) were treated with chemotherapy for the first cancer, and 25 (58%) were treated with radiotherapy for the first cancer. Second cancers within this group included breast cancer in 25 (58%), colorectal cancer in 9 (21%), and lung cancer in 9 (21%). Third cancers included breast cancer in 16 (37%), colorectal cancer in 6 (14%), lung cancer in 18 (42%), ovarian cancer in 1 (2%), pancreatic cancer in 1 (2%), and another type of cancer in 1 (2%). Twenty-eight patients remain alive at the time of this report; the rate of overall median survival was 16 years. Among the 15 deceased patients, the cause of death was related to cancer in 9 cases.
Discussion
This study focused on patients diagnosed with 3 or more common, invasive, and sometimes lethal malignancies. It was not intended to report on the prevalence rates of patients with multiple cancers because our eligibility criteria were deliberatively selective; however, the scenario of multiple cancers appears to be rare, particularly when considering the number of cancer diagnoses every year at our institution -868 patients were diagnosed with breast cancer in 2014 at the Mayo Clinic alone (unpublished data) -and when acknowledging that cancer remains a major cause of death around the world. 10 We have identified a small cohort of patients who illustrate this clinical scenario. This study contributes to a small but growing body of literature that reports on the development of multiple cancers in a group of patients who have not been specifically selected based on a genetic or otherwise known predisposition for having a higher risk of cancer. 4, 11 Despite the presumed rarity of this clinical scenario, this study provides important insights. These patients often develop an early-stage malignancy, undergo surgical resection, and then live for many years prior to developing a subsequent malignancy that can be treated in a similar fashion. The median survival for the study group exceeded 10 years, underscoring the fact that this subgroup is treated and then re-treated for a new cancer over time. Thus, a history of more than 1 early-stage cancer should not negatively impact the management of subsequent early-stage cancers. In addition, although comparisons across data sets are perilous and, although our sample size is too small to allow for formal adjusted comparisons across data sets, when we examined patients who were first diagnosed with breast cancer and then developed multiple malignances thereafter, we did not observe major differences in survival based on benchmark data. 9 For example, the latter shows that 88% of patients with breast cancer reached the 5-year mark, 9 whereas a survival curve from patients with breast cancer in our study shows that more than 90% did the same (data not shown).
Risk factors for early death remain relevant to patients with multiple cancers. Older age, smoking, and stage IV disease are all associated with poor survival in patients with multiple cancers. These prognostic factors remain important regardless of whether a patient has been diagnosed with 1 cancer type or several.
More than 40% of the patients in our study were diagnosed with 4 or more cancers. Although old age is a risk factor for cancer, the patients in the current study were not elderly when diagnosed with their first malignancy (median age, 61 years). Moreover, a small percentage had a known syndrome that predisposed them to cancer or a compelling reason to suspect that their history of recurrent cancers was the result of prior cancer therapy, although our understanding of genetic predisposition to cancer has grown over the years. However, many of these patients were treated surgically -a therapy not generally known to spawn secondary cancers. Thus, perhaps other, undiscovered factors are at play to explain the development of multiple cancers. This potential for uncharacterized risk factors for cancer -including genetic factors -requires further investigation.
Limitations
The retrospective design of our study is a limitation and led to missing data in some instances, as is the case in any retrospective study. However, by using a retrospective design, we were able to assess 20 years of data within a short time frame. Another limitation is our small sample size, which is the result of our single-institution study design. However, our single-institution focus enabled us to acquire detailed information on the dates, cancer stage, cancer therapy, and, in some cases, causes of death. The single-institution nature of our study may have also allowed for a greater degree of homogeneity among data elements, thereby enabling us to identify conclusions more readily.
Conclusions
Patients diagnosed with multiple cancers may continue to live for years. To our knowledge, little insight exists in the literature on the attitudes of health care professionals toward patients with a history of multiple malignancies, and repeated cancer diagnoses followed by a cumulative history of cancer treatment could conceivably lead to a biased approach to repeat cancer therapy over time. The findings from this study underscore the need to continue to try to apply curative therapy to patients with a history of multiple cancers, regardless of whether these cancers are primary, secondary, or tertiary. These findings also suggest the need to further investigate the prevalence and risk factors for the development of multiple cancers.
